It may be that comorbidities, cancer status, and cancer therapy affected the physician’s decision [6].Cancer patients were excluded from HF clinical trials with ACE-I, beta-blockers, mineralocorticoid receptors, and statins and we do not have data on their efficacy in the cancer HF population [26]. This evidence concerns the gene NR3C2 and cancer.